Growth hormone deficiency and other endocrinopathies after childhood brain tumors: results from a close follow-up in a cohort of 242 patients
ConclusionThis study reveals a higher prevalence of endocrinopathies in brain tumors survivors and explores the influence of craniospinal irradiation in the adult body proportions. It reinforces the importance of routine follow-up among survivors. (Source: Journal of Endocrinological Investigation)
Source: Journal of Endocrinological Investigation - October 10, 2021 Category: Endocrinology Source Type: research
The future of somatostatin receptor ligands in acromegaly
J Clin Endocrinol Metab. 2021 Oct 7:dgab726. doi: 10.1210/clinem/dgab726. Online ahead of print.ABSTRACTCurrently, first-generation somatostatin receptor ligands (fg-SRLs), octreotide LAR and lanreotide autogel, are the mainstays of acromegaly treatment and achieve biochemical control in approximately 40% of patients and tumor shrinkage in over 60% of patients. Pasireotide, a second-generation SRL, shows higher efficacy with respect to both biochemical control and tumor shrinkage but has a worse safety profile. In this review, we discuss the future perspectives of currently available SRLs, focusing on the use of biomarkers...
Source: The Journal of Clinical Endocrinology and Metabolism - October 7, 2021 Category: Endocrinology Authors: Monica R Gadelha Luiz Eduardo Wildemberg Leandro Kasuki Source Type: research
The future of somatostatin receptor ligands in acromegaly
J Clin Endocrinol Metab. 2021 Oct 7:dgab726. doi: 10.1210/clinem/dgab726. Online ahead of print.ABSTRACTCurrently, first-generation somatostatin receptor ligands (fg-SRLs), octreotide LAR and lanreotide autogel, are the mainstays of acromegaly treatment and achieve biochemical control in approximately 40% of patients and tumor shrinkage in over 60% of patients. Pasireotide, a second-generation SRL, shows higher efficacy with respect to both biochemical control and tumor shrinkage but has a worse safety profile. In this review, we discuss the future perspectives of currently available SRLs, focusing on the use of biomarkers...
Source: The Journal of Clinical Endocrinology and Metabolism - October 7, 2021 Category: Endocrinology Authors: Monica R Gadelha Luiz Eduardo Wildemberg Leandro Kasuki Source Type: research
Suboptimal Adherence to daily growth hormone in a US real-world study: an unmet need in the treatment of pediatric growth hormone deficiency
CONCLUSION: Suboptimal adherence increases with treatment duration, and risk of discontinuation is associated with age, female gender, black or Hispanic race/ethnicity, and obesity. Strategies that facilitate adherence among children at risk of discontinuation may improve clinical outcomes.PMID:34569388 | DOI:10.1080/03007995.2021.1982682 (Source: Current Medical Research and Opinion)
Source: Current Medical Research and Opinion - September 27, 2021 Category: Research Authors: Jane Loftus Yong Chen Jose Ma J Alvir Lei Chi Shibasish Dasgupta Anu Gupta Michael P Wajnrajch Source Type: research
Weekly Lonapegsomatropin in Treatment-Na ïve Children with Growth Hormone Deficiency: The Phase 3 heiGHt Trial
CONCLUSIONS: The trial met its primary objective of non-inferiority in AHV and further showed superiority of lonapegsomatropin compared to daily somatropin, with similar safety, in treatment-naïve children with GHD.PMID:34272849 | DOI:10.1210/clinem/dgab529 (Source: The Journal of Clinical Endocrinology and Metabolism)
Source: The Journal of Clinical Endocrinology and Metabolism - July 17, 2021 Category: Endocrinology Authors: Paul S Thornton Aristides K Maniatis Elena Aghajanova Elena Chertok Elpis Vlachopapadopoulou Zhengning Lin Wenjie Song Eva Dam Christoffersen Vibeke Miller Breinholt Tatiana Kovalenko Elene Giorgadze Maria Korpal-Szczyrska Paul L Hofman David B Karpf Aime Source Type: research
Weekly Lonapegsomatropin in Treatment-Na ïve Children with Growth Hormone Deficiency: The Phase 3 heiGHt Trial
CONCLUSIONS: The trial met its primary objective of non-inferiority in AHV and further showed superiority of lonapegsomatropin compared to daily somatropin, with similar safety, in treatment-naïve children with GHD.PMID:34272849 | DOI:10.1210/clinem/dgab529 (Source: The Journal of Clinical Endocrinology and Metabolism)
Source: The Journal of Clinical Endocrinology and Metabolism - July 17, 2021 Category: Endocrinology Authors: Paul S Thornton Aristides K Maniatis Elena Aghajanova Elena Chertok Elpis Vlachopapadopoulou Zhengning Lin Wenjie Song Eva Dam Christoffersen Vibeke Miller Breinholt Tatiana Kovalenko Elene Giorgadze Maria Korpal-Szczyrska Paul L Hofman David B Karpf Aime Source Type: research
Safety and Effectiveness of Recombinant Human Growth Hormone in Children with Turner Syndrome: Data from the PATRO Children Study
Conclusion: These data suggest that biosimilar rhGH is well tolerated and effective in TS patients managed in real-life clinical practice. Optimization of rhGH dose may contribute to a higher AH.Horm Res Paediatr (Source: Hormone Research in Paediatrics)
Source: Hormone Research in Paediatrics - July 7, 2021 Category: Endocrinology Source Type: research
Effectiveness and Overall Safety of NutropinAq ® for Growth Hormone Deficiency and Other Paediatric Growth Hormone Disorders: Completion of the International Cooperative Growth Study, NutropinAq® European Registry (iNCGS)
ConclusionsThere was an improvement in mean height SDS in all aetiology subgroups after rhGH treatment. No new safety concerns were identified. (Source: Frontiers in Endocrinology)
Source: Frontiers in Endocrinology - May 25, 2021 Category: Endocrinology Source Type: research
Continued Efficacy and Safety with up to 2 Years of Treatment with Lonapegsomatropin (TransCon hGH) in Children with Growth Hormone Deficiency
Once-weekly lonapegsomatropin (TransCon hGH) is an investigational prodrug of somatropin in development for treatment of growth hormone deficiency (GHD). Lonapegsomatropin demonstrated efficacy and safety in both treatment-na ïve and treatment-experienced children in the 52-week heiGHt Trial and 26-week fliGHt Trial, respectively. (Source: Journal of Pediatric Nursing)
Source: Journal of Pediatric Nursing - May 1, 2021 Category: Nursing Authors: Donna Campbell, Kimberly Walsh, Natalie Marlen, Wenjie Song, Meng Mao, Steven Chessle, Allison Komirenko, Michael Beckert, Aimee D. Shu Source Type: research
Growth hormone deficiency and other endocrinopathies after childhood brain tumors: results from a close follow-up in a cohort of 242 patients
ConclusionThis study reveals a higher prevalence of endocrinopathies in brain tumors survivors and explores the influence of craniospinal irradiation in the adult body proportions. It reinforces the importance of routine follow-up among survivors. (Source: Journal of Endocrinological Investigation)
Source: Journal of Endocrinological Investigation - March 8, 2021 Category: Endocrinology Source Type: research
The value of a simple method to decrease diagnostic errors in Turner syndrome: a case report
ConclusionThe diagnosis of this case was not straightforward, both because the somatic presentations were not obvious, and because the physicians had not looked for them when performing the physical examinations. This case report introduces a rare 44,X chromosome karyotype of Turner syndrome and highlights the value in using the difference between target height and patient height standard deviation scores as a simple and inexpensive tool for diagnosis of this syndrome. (Source: Journal of Medical Case Reports)
Source: Journal of Medical Case Reports - February 18, 2021 Category: General Medicine Source Type: research
Adherence to growth hormone therapy guidelines in a real-world French cohort of adult patients with growth hormone deficiency.
CONCLUSION: Current clinical practice of physicians in France follows international guidelines regarding somatropin dose adjustment in adults with GHD. However, dose adjustments are not always sufficient, notably in women, and treatment effects may have been delayed due to low somatropin dose. (Clinical trial registration NCT01580605).
PMID: 33290752 [PubMed - as supplied by publisher] (Source: Annales d'Endocrinologie)
Source: Annales d'Endocrinologie - December 5, 2020 Category: Endocrinology Authors: Borson-Chazot F, Chabre O, Salenave S, Klein M, Brac de la Perriere A, Reznik Y, Kerlan V, Hacques E, Villette B Tags: Ann Endocrinol (Paris) Source Type: research
Nasal Absorption Enhancement of Protein Drugs Independent to Their Chemical Properties in the Presence of Hyaluronic Acid Modified with Tetraglycine-L-octaarginine.
Abstract
Our previous mouse studies demonstrated that mean bioavailability of exendin-4, which is an injectable glucagon-like peptide-1 (GLP-1) analogue whose molecular weight (Mw) and isoelectric point (pI) are ca. 4.2 kDa and 4.5, respectively, administered nasally with poly(N-vinylacetamide-co-acrylic acid) (PNVA-co-AA) bearing D-octaarginine, which is a typical cell-penetrating peptide, was 20% relative to subcutaneous administration even though it was less than 1% when exendin-4 alone was given nasally. The studies also revealed that the absorption-enhancing ability of D-octaarginine-linked PNVA-co-AA...
Source: European Journal of Pharmaceutics and Biopharmaceutics - July 14, 2020 Category: Drugs & Pharmacology Authors: Tomono T, Yagi H, Ukawa M, Ishizaki S, Miwa T, Nonomura M, Igi R, Kumagai H, Miyata K, Tobita E, Kobayashi H, Sakuma S Tags: Eur J Pharm Biopharm Source Type: research
Safety and effectiveness of a somatropin biosimilar in children requiring growth hormone treatment: second analysis of the PATRO Children study Italian cohort
ConclusionsIn this sub-analysis of PATRO Children, Omnitrope® appeared to have acceptable safety and effectiveness in the treatment of in Italian children, which was consistent with the earlier findings from controlled clinical trials. (Source: Journal of Endocrinological Investigation)
Source: Journal of Endocrinological Investigation - June 14, 2020 Category: Endocrinology Source Type: research
IJERPH, Vol. 17, Pages 4113: Physician-Level Cost Control Measures and Regional Variation of Biosimilar Utilization in Germany
ndt
Biologic drugs represent a large and growing portion of health expenditures. Increasing the use of biosimilars is a promising option for controlling spending growth in pharmaceutical care. Amid the considerable uncertainty concerning physicians’ decision to prescribe biosimilars, explicit cost control measures may help increase biosimilar use. We analyze the role of regional cost control measures for biosimilars and their association with physician prescriptions in ambulatory care in Germany. We collect data on cost control measures implemented by German physician associations and national claims data...
Source: International Journal of Environmental Research and Public Health - June 8, 2020 Category: Environmental Health Authors: Katharina E. Blankart Friederike Arndt Tags: Article Source Type: research
